Clinical trials: Severe Respiratory Distress
Influenza, Avian Influenza
High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths…
- Conditions
- Influenza, Avian Influenza, Severe Influenza
- Trial name
- NCT00298233
- Testing
- Oseltamivir
- Where
- 12 sites in Singapore, Thailand and 1 more
- Volunteers
- 326 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, Sars-CoV-2 Infection
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
The positive cases of coronavirus disease-2019 (COVID-19) in Indonesia has been increasing rapidly since the first case found in March 2020 to date.
- Conditions
- Covid19, Sars-CoV-2 Infection, ARDS, Human, Severe covid19
- Trial name
- NCT04715360
- Testing
- autologous activated platelet-rich plasma, Avigan
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- Hayandra Peduli Foundation
Infant, Newborn, Infant, Low Birth Weight
Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure
This multicenter trial tested whether inhaled nitric oxide would reduce death or the need for oxygen in preterm infants (less than 34 weeks gestational age) with severe lung disease.
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
- Trial name
- Preemie iNO (NCT00016523)
- Testing
- Inhaled nitric oxide
- Where
- 17 sites in United States
- Volunteers
- 420 people
- Sponsor
- NICHD Neonatal Research Network
Respiratory Distress Syndrome, Positive-Pressure Respiration
Personalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability
This observational study will explore the effects of PEEP and position on regional lung ventilation-perfusion mismatch by electrical impedance tomography (EIT) in moderate-to-severe ARDS patients with different lung…
- Conditions
- Respiratory Distress Syndrome, Positive-Pressure Respiration, Mechanical Ventilation
- Trial name
- NCT06430554
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhongda Hospital
Asthma
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016)…
- Trial name
- NCT02555683
- Testing
- QAW039
- Where
- 234 sites in United States, Argentina and 25 more
- Volunteers
- 894 people
- Sponsor
- Novartis Pharmaceuticals
Severe Pneumonia, Acute Respiratory Distress Syndrome
Treatment of COVID-19 Positive/Negative Bangladeshi Adults With Severe Respiratory Complaints by a Locally Made bCPAP: Feasibility Study
Low and middle-income countries (LMICs) urgently need cost-effective adaptive technologies to provide CPAP. The lead investigator has designed a device that has already been approved by the Directorate General of Drug…
- Conditions
- Severe Pneumonia, Acute Respiratory Distress Syndrome, Covid19
- Trial name
- Adult-bCPAP (NCT05158842)
- Testing
- Adult bubble CPAP oxygen therapy device
- Where
- 2 sites in Bangladesh
- Volunteers
- 20 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Respiratory Failure, Acute Respiratory Distress Syndrome
Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients
The Acute Respiratory Distress Syndrome (ARDS) is one of common clinical critically diseases. In the United States, the incidence of ARDS reaches 31%, which is one of the main causes of death in patients.
- Trial name
- NCT02814994
- Testing
- tidal volume guided by respiratory system compliance, low tidal volume
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Southeast University, China
Bronchiolitis, Viral
Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age
Background. Viral bronchiolitis is a common cause of hospitalization for acute respiratory insufficiency in young infants. Despite several RCT have tested the effectiveness of various agents, currently there is no proven specific…
- Trial name
- NCT03959384
- Testing
- Curosurf 80Mg/Ml Intratracheal Suspension, Ambient Air
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Dyspnea, COVID-19
Two-year Efficacy of Three Exercise Rehabilitation Strategies on Dyspnea in Patients Who Presented With Secondary Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia
Dyspnea is defined by a subjective sensation of respiratory discomfort, the intensity of which varies according to the terrain, the anamnesis and the cause.
- Trial name
- RECOVER_FU (NCT05890560)
- Where
- 4 sites in France
- Volunteers
- 120 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
Little Lungs Study
This clinical trial is being done to evaluate the safety and clinical response of late surfactant treatment with budesonide in extremely preterm infants requiring mechanical ventilation at 7-14 days of age.
- Trial name
- NCT06855043
- Testing
- Calfactant, Budesonide
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Wisconsin, Madison
Acute Respiratory Distress Syndrome
A Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Severe Acute Respiratory Distress Syndrome
Primary Objective: To evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection in the treatment of moderate/severe acute respiratory distress syndrome.Secondary Objectives: To explore the…
- Trial name
- ARDS (NCT07413978)
- Testing
- 1 vial containing a total of 5×10^7 cells, 2 vial containing a total of 1×10^8 cells, 3 vial containing a total of 1.5×10^8 cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Changchun Tuohua Pharmaceutical Co., Ltd.
Respiratory Distress Syndrome, Adult
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)
In this study effectiveness and safety of a new drug FP-1201-lyo (recombinant human interferon beta-1a) is compared to placebo. Investigation is conducted with patients who have acute respiratory distress syndrome (ARDS).
- Trial name
- INTEREST (NCT02622724)
- Testing
- Interferon beta-1a
- Where
- 71 sites in Belgium, Czechia and 6 more
- Volunteers
- 301 people
- Sponsor
- Faron Pharmaceuticals Ltd
COVID-19, SARS-CoV-2 Infection
Clinical Characteristics and Outcomes of Pediatric COVID-19
Rationale: The clinical manifestations of SARS-CoV-2 infection in children are poorly characterized. Preliminary findings indicate that they may be atypical.
- Conditions
- COVID-19, SARS-CoV-2 Infection, Pediatric ALL, Pneumonia, Viral
- Trial name
- PERN-COVID-19 (NCT04330261)
- Testing
- Exposure (not intervention) - SARS-CoV-2 infection
- Where
- Canada
- Volunteers
- 10,610 people
- Sponsor
- University of Calgary
Acute Respiratory Distress Syndrome
Ultra Protective Ventilation Without Extracorporeal Circulation in Severe ARDS Patients (VT4ARDS)
Despite the use of protective ventilation, neuromuscular blocking agent and prone position, ARDS mortality remains high (30%-50%) in observational studies, and pneumothorax rate in randomized controlled trial remains stable…
- Trial name
- VT4ARDS (NCT02816372)
- Testing
- Tidal volume reduction to 4 ml/kg Predicted Body Weight (PBW)
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Hospices Civils de Lyon
Acute Respiratory Distress Syndrome, SARS-CoV-2
Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19
- Trial name
- NCT04565249
- Testing
- PLN-74809
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pliant Therapeutics, Inc.
ARDS: Acute Respiratory Distress Syndrome, Covid19
Single-cell Landscape of BALF in Patients With Severe ARDS and CARDS
The goal of this observational study is to learn about the effect of steroid therapy in patients with COVID-19 ARDS. The main questions it aims to answer are: Differences between patients with COVID-19 ARDS before and after…
- Trial name
- NCT05933291
- Testing
- steroid
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Peking Union Medical College Hospital
Depression, Burnout, Professional
Health cAre woRkers exposeD to COVID-19
Health care workers working in hospital or nursing home for elderly people involved in the coronavirus epidemic are facing several challenges such as direct exposure and involvement in the resolution of major public health…
- Conditions
- Depression, Burnout, Professional, Post Traumatic Stress Disorder
- Trial name
- HARD-COVID19 (NCT04570202)
- Testing
- EMDR
- Where
- 2 sites in France
- Volunteers
- 900 people
- Sponsor
- University Hospital, Tours
Acute Respiratory Distress Syndrome, Infections
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS…
- Trial name
- NCT05947955
- Testing
- Rhu-pGSN, normal saline
- Where
- 65 sites in United States, Belgium and 11 more
- Volunteers
- 600 people
- Sponsor
- BioAegis Therapeutics Inc.
Sepsis, Pneumonia
Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System
High mortality associated with sepsis and Multiple Organ Dysfunction Syndrome (MODS) calls for alternative, individualized therapies in selected patients that might benefit form specific interventions.
- Conditions
- Sepsis, Pneumonia, Gram-Negative Bacteria Infection, Multiple Organ Failure
- Trial name
- INCLASS (NCT03345992)
- Testing
- Clarithromycin, Water for injection
- Where
- 12 sites in Belgium, Greece
- Volunteers
- 110 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Covid-19
Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19
Describes the cohort of patients receiving ECMO-VV or ECMO-VA in the management of severe ARDS refractory to SARS-CoV-2 in the Strasbourg and Louvain centres
- Trial name
- ECMO-SL-CoV-2 (NCT04446286)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France